• Français

• Home
• About CQDM
  • Mission and Objectives
  • Areas of Activity
  • Business Model
  • Annual Report
  • Partners
  • Collaborators
  • Team
  • Structure and Governance
    • Board of Directors
    • Executive Committee
    • Strategic Orientation Committee
    • Explore Advisory Committee
• Competition and Funding
  • FOCUS Competition
    • General Information
    • Current Competition
    • Previous Competitions
  • EXPLORE Competition
    • General Information
    • Current Competition
    • Previous Competitions
  • CQDM/Alsace BioValley Joint Program
    • General Information
    • Current Competition
    • Previous Competitions
• Funded
  Projects
  • FOCUS Competition
  • EXPLORE Competition
  • CQDM/Alsace BioValley Joint Program
• Drug Meeting Ground
  • Forums of Exchange
  • The Most Important Contributions in Biomedical Research in Québec
• News
  • CQDM News
  • News of the Researchers and Companies Funded by CQDM
• Press
  Articles
• Contact

• FOCUS Competition
  • General Information
  • Current Competition
  • Previous Competitions
• EXPLORE Competition
  • General Information
  • Current Competition
  • Previous Competitions
• CQDM/Alsace BioValley Joint Program
  • General Information
  • Current Competition
  • Previous Competitions

Competition and Funding / CQDM/Alsace BioValley Joint Program

2011 competition

In the course of this program, 5 projects were submitted to the CQDM. Following this competition, 2 outstanding research projects were selected. These projects involve researchers from 3 universities and 4 private companies from Quebec and Alsace.

Visualization and monitoring of receptor-effector complexes activity in vivo. Michel Bouvier (IRIC, Université de Montréal; Quebec), Mispro (Montreal; Quebec), Brigitte Kieffer (IGBMC, GIE-CERBM; Alsace) and Pascal Neuville (Domain Therapeutics; Alsace).

This project aims to generate genetically modified mice that will allow direct observation of the action of molecules on the G protein-coupled receptors using an innovative microscopic imaging technique. These new animal models will permit the visualization of the effects of target molecules at the cellular and molecular level hence facilitating the development of drugs with greater therapeutic efficacy and less undesirable side effects.

Development and validation of two synergistic platforms based on imaging and biosimulation to visualize the action of drug candidates at the subcellular and molecular levels. Sébastien Blais-Ouellette (Photon etc.; Quebec), Paul de Koninck (Université Laval; Quebec) and Serge Bischoff (Rhenovia Pharma; Alsace).

The synergy between the expertise of the collaborators will lead to the development of two innovative platforms to facilitate drug discovery and development: 1) an imaging platform used to study the effect of drugs on the dynamics of neuronal proteins and 2) a biosimulation platform for integrating signaling mechanisms at the synapse level to model and predict the effect of candidate drugs on neuronal functions.

 

Pilot project 2010

A first call for proposals "pilot" has already been lunched in 2010 and led to the selection of the following research project:

Identification of new biomarkers for neuroendocrine cancers. Daniel Chelsky and Eustache Paramithiotis (Caprion Proteomics Inc.; Quebec) and Stéphane Gasman (Centre National de la Recherche Scientifique, Strasbourg; Alsace)

This collaborative project aims to: 1) investigate the mechanisms resulting in neuroendocrine tumour hyper-secretion, and identify the changes undergone by the tumour-secreted proteins and 2) identify candidate secretory protein biomarkers with the potential to generate better diagnostic and prognostic markers. Ultimately, the team will be able to discover new cancerous proteins which can become the targets of improved diagnostics and therapies.